Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
Abstract Background To investigate the prognostic relevance of the time to interval debulking surgery (TTS) and the time to postoperative adjuvant chemotherapy (TTC) after the completion of neoadjuvant chemotherapy (NACT). Methods A retrospective real-word study included 658 patients with histologic...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-06-01
|
| Series: | Journal of Ovarian Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13048-023-01164-8 |
| _version_ | 1827910623189532672 |
|---|---|
| author | Xingyu Liu Yingjun Zhao Xiaofei Jiao Yang Yu Ruyuan Li Shaoqing Zeng Jianhua Chi Guanchen Ma Yabing Huo Ming Li Zikun Peng Jiahao Liu Qi Zhou Dongling Zou Li Wang Qingshui Li Jing Wang Shuzhong Yao Youguo Chen Ding Ma Ting Hu Qinglei Gao |
| author_facet | Xingyu Liu Yingjun Zhao Xiaofei Jiao Yang Yu Ruyuan Li Shaoqing Zeng Jianhua Chi Guanchen Ma Yabing Huo Ming Li Zikun Peng Jiahao Liu Qi Zhou Dongling Zou Li Wang Qingshui Li Jing Wang Shuzhong Yao Youguo Chen Ding Ma Ting Hu Qinglei Gao |
| author_sort | Xingyu Liu |
| collection | DOAJ |
| description | Abstract Background To investigate the prognostic relevance of the time to interval debulking surgery (TTS) and the time to postoperative adjuvant chemotherapy (TTC) after the completion of neoadjuvant chemotherapy (NACT). Methods A retrospective real-word study included 658 patients with histologically confirmed advanced epithelial ovarian cancer who received NACT at seven tertiary hospitals in China from June 2008 to June 2020. TTS was defined as the time interval from the completion of NACT to the time of interval debulking surgery (IDS). TTC was defined as the time interval from the completion of NACT to the initiation of postoperative adjuvant chemotherapy (PACT). Results The median TTS and TTC were 25 (IQR, 20–29) and 40 (IQR, 33–49) days, respectively. Patients with TTS > 25 days were older (55 vs. 53 years, P = 0.012) and received more NACT cycles (median, 3 vs. 2, P = 0.002). Similar results were observed in patients with TTC > 40 days. In the multivariate analyses, TTS and TTC were not associated with PFS when stratified by median, quartile, or integrated as continuous variables (all P > 0.05). However, TTS and TTC were significantly associated with worse OS when stratified by median (P = 0.018 and 0.018, respectively), quartile (P = 0.169, 0.014, 0.027 and 0.012, 0.001, 0.033, respectively), or integrated as continuous variables (P = 0.018 and 0.011, respectively). Similarly, increasing TTS and TTC intervals were associated with a higher risk of death (P trend = 0.016 and 0.031, respectively) but not with recurrence (P trend = 0.103 and 0.381, respectively). Conclusion The delays of IDS and PACT after the completion of NACT have adverse impacts on OS but no impacts on PFS, which indicates that reducing delays of IDS and PACT might ameliorate the outcomes of ovarian cancer patients treated with NACT. |
| first_indexed | 2024-03-13T01:53:22Z |
| format | Article |
| id | doaj.art-4e7937dc5f0642788234b236058d272a |
| institution | Directory Open Access Journal |
| issn | 1757-2215 |
| language | English |
| last_indexed | 2024-03-13T01:53:22Z |
| publishDate | 2023-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Ovarian Research |
| spelling | doaj.art-4e7937dc5f0642788234b236058d272a2023-07-02T11:23:03ZengBMCJournal of Ovarian Research1757-22152023-06-0116111110.1186/s13048-023-01164-8Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world studyXingyu Liu0Yingjun Zhao1Xiaofei Jiao2Yang Yu3Ruyuan Li4Shaoqing Zeng5Jianhua Chi6Guanchen Ma7Yabing Huo8Ming Li9Zikun Peng10Jiahao Liu11Qi Zhou12Dongling Zou13Li Wang14Qingshui Li15Jing Wang16Shuzhong Yao17Youguo Chen18Ding Ma19Ting Hu20Qinglei Gao21Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Gynecologic Oncology, Chongqing University Cancer HospitalDepartment of Gynecologic Oncology, Chongqing University Cancer HospitalDepartment of Cancer Biology Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer HospitalDepartment of Gynecologic Oncology, Shandong Cancer Hospital and InstituteHunan Clinical Research Center in Gynecologic Cancer, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South UniversityDepartment of Obstetrics and Gynecology, the First Affiliated Hospital, Sun Yat-sen UniversityDepartment of Gynecology & Obstetrics, the First Affiliated Hospital of Soochow UniversityDepartment of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAbstract Background To investigate the prognostic relevance of the time to interval debulking surgery (TTS) and the time to postoperative adjuvant chemotherapy (TTC) after the completion of neoadjuvant chemotherapy (NACT). Methods A retrospective real-word study included 658 patients with histologically confirmed advanced epithelial ovarian cancer who received NACT at seven tertiary hospitals in China from June 2008 to June 2020. TTS was defined as the time interval from the completion of NACT to the time of interval debulking surgery (IDS). TTC was defined as the time interval from the completion of NACT to the initiation of postoperative adjuvant chemotherapy (PACT). Results The median TTS and TTC were 25 (IQR, 20–29) and 40 (IQR, 33–49) days, respectively. Patients with TTS > 25 days were older (55 vs. 53 years, P = 0.012) and received more NACT cycles (median, 3 vs. 2, P = 0.002). Similar results were observed in patients with TTC > 40 days. In the multivariate analyses, TTS and TTC were not associated with PFS when stratified by median, quartile, or integrated as continuous variables (all P > 0.05). However, TTS and TTC were significantly associated with worse OS when stratified by median (P = 0.018 and 0.018, respectively), quartile (P = 0.169, 0.014, 0.027 and 0.012, 0.001, 0.033, respectively), or integrated as continuous variables (P = 0.018 and 0.011, respectively). Similarly, increasing TTS and TTC intervals were associated with a higher risk of death (P trend = 0.016 and 0.031, respectively) but not with recurrence (P trend = 0.103 and 0.381, respectively). Conclusion The delays of IDS and PACT after the completion of NACT have adverse impacts on OS but no impacts on PFS, which indicates that reducing delays of IDS and PACT might ameliorate the outcomes of ovarian cancer patients treated with NACT.https://doi.org/10.1186/s13048-023-01164-8Neoadjuvant chemotherapyTime to interval debulking surgeryTime to postoperative adjuvant chemotherapyAdvanced epithelial ovarian cancerPrognosis |
| spellingShingle | Xingyu Liu Yingjun Zhao Xiaofei Jiao Yang Yu Ruyuan Li Shaoqing Zeng Jianhua Chi Guanchen Ma Yabing Huo Ming Li Zikun Peng Jiahao Liu Qi Zhou Dongling Zou Li Wang Qingshui Li Jing Wang Shuzhong Yao Youguo Chen Ding Ma Ting Hu Qinglei Gao Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study Journal of Ovarian Research Neoadjuvant chemotherapy Time to interval debulking surgery Time to postoperative adjuvant chemotherapy Advanced epithelial ovarian cancer Prognosis |
| title | Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study |
| title_full | Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study |
| title_fullStr | Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study |
| title_full_unstemmed | Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study |
| title_short | Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study |
| title_sort | timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer a multicenter real world study |
| topic | Neoadjuvant chemotherapy Time to interval debulking surgery Time to postoperative adjuvant chemotherapy Advanced epithelial ovarian cancer Prognosis |
| url | https://doi.org/10.1186/s13048-023-01164-8 |
| work_keys_str_mv | AT xingyuliu timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT yingjunzhao timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT xiaofeijiao timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT yangyu timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT ruyuanli timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT shaoqingzeng timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT jianhuachi timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT guanchenma timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT yabinghuo timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT mingli timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT zikunpeng timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT jiahaoliu timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT qizhou timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT donglingzou timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT liwang timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT qingshuili timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT jingwang timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT shuzhongyao timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT youguochen timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT dingma timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT tinghu timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy AT qingleigao timingofintervaldebulkingsurgeryandpostoperativechemotherapyafterneoadjuvantchemotherapyinadvancedepithelialovariancanceramulticenterrealworldstudy |